Updates on the latest news and insights from Esperante and its portfolio.
![Medicenna](https://www.esperante.com/wp-content/uploads/2022/05/blog_medicenna-404x195.jpg)
17 November 2023 Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that a poster presentation...
![Medicenna](https://www.esperante.com/wp-content/uploads/2022/05/blog_medicenna-404x195.jpg)
6 November 2023 Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that new clinical data from the...
![Pneumagen](https://www.esperante.com/wp-content/uploads/2023/06/blog_pneumagen-404x195.jpg)
2 October 2023 Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), today announced...
![Spiral Therapeutics](https://www.esperante.com/wp-content/uploads/2023/06/blog_spiral-therapeutics-404x195.jpg)
30 August 2023 Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, today announced today that it has been recognized for its innovative...
![Spiral Therapeutics](https://www.esperante.com/wp-content/uploads/2023/06/blog_spiral-therapeutics-404x195.jpg)
30 August 2023 Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, today announced a new round of financing led by Esperante Ventures...
![AMLo Biosciences](https://www.esperante.com/wp-content/uploads/2023/08/blog_amlo-404x195.jpg)
1 August 2023 New data further validates AMBLor® biomarker diagnostic test in the stratification of low-risk melanomas With skin cancer being the most commonly diagnosed cancer in the US and the percentage...